China cobra venom active factor (CCVAF) inhibits VEGF and bFGF in lung cancer cell line H1299

Abstract

Abstract: AIM: To study the effect of China cobra venom active factor (CCVAF) on the expression of VEGF and bFGF in human non-small cell lung cancer cell line H1299.METHODS: VEGF and bFGF mRNA level was measured by RT-PCR.VEGF and bFGF protein level in the supernatant was examined by ELISA.RESULTS: The mRNA expression level of bFGF was also reduced after treatment with the CCVAF in dose-dependent manner. Giving the CCVAF 4.0 μg·ml^-1 to cell H1299 for 4 hours could notablely decreased the mRNA expression of bFGF while it had no such effect on VEGF mRNA expression level.The content of VEGF, and bFGF in supernatant of H1299 cells were significantly decreased after treatment for 24 hour with CCVAF in dose-dependent manner.There was significant difference compared with control group (P <0.05).CONCLUSION: CCVAF inhibits the expression of VEGF and bFGF in H1299 cells.

Key words: China cobra venom, lung cancer cell, RT-PCR, ELISA, VEGF, bFGF

CLC Number:

R979.1

YU Hong-e, YU Qing-sheng, LIU Xin-yan, ZHU Liu, LOU Xiao-hua, TENG Mai-kun. China cobra venom active factor (CCVAF) inhibits VEGF and bFGF in lung cancer cell line H1299[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(9): 970-973.

References

1 Folkman J.Clinical applications of research on angiogenesis [J].N Eng J Med, 1995;333:1757-63
2 Aonuma M, Iwahana M, Nakayama Y, Hirotani K, Hattori C, Murakami K, et al.Tumorigenicity depends on angiogenic potential of tumor cells:dominant role of vascular endothelial growth factor and/or fibroblast growth factors produced by tumor cells[J].Angiogenesis, 1998;2:57-66
3 孙林光, 余清声, 廖兆全, 赵路宁, 管锦霞.中华眼镜蛇毒组分M 抑制血小板聚集作用机制初探[J].广州医学院学报, 1999;27:1-4
4 杨惠玲, 余清声, 简志瀚, 郑芹, 龚海云.中华眼镜蛇毒对人鼻咽癌等抑瘤作用的实验研究[J].癌症, 1999;18:27-9
5 刘晓颖, 余清声, 覃媛.中华眼镜蛇毒活性组分抑血管内皮细胞增殖和粘附实验研究[J].血栓与止血学, 2004;10:19-21
6 余清声, 刘晓颖, 覃嫒, 黄劭.中华眼镜蛇毒F 组分体外抑制三维血管生成的实验研究[J].中国临床药理学与治疗学, 2004;9:1105-9
7 杨竹林, 李永国, 钟德玕, 王群伟, 吕芳.胆系恶性肿瘤VEGF、bFGF 的表达与微血管计数的关系[J].中华普通外科杂志, 2000;15:558-62
8 Brattstrom D, Bergqvist M, Hesselius P, Larsson A, Wagenius G, Brodin O.Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer[J].Lung Cancer, 2004;43:55-62
9 Komorowski J, Jankewica J, Stepien H.Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble interleukin-2 receptor(Sil-2R) concentrations in peripheral blood as markers of pituitary tumors[J].Vtobios, 2000;101:151-9
10 Kos M, Dabrowsk A.Tumour's angiogenesis-the function of VEGF and bFGF in colorectal cancer[J].Ann Univ Mariae Curie Sklodowska, 2002;57:556-61
11 Dvorak HF, Brown LF, Detmar M, Dvorak AM.Vascular permeability factor/Vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis[J].Am J Pathol, 1995;146:1029-39
12 Kang IC, Lee YD, Kim DS.A novel disintegrin salmosin inhibits tumor angiogenesis[J].Cancer Res, 1999;59:3754-60
13 Zhou Q, Nakada MT, Arnold C, Shieh KY, Markland FS JR. Contortrostatin, a dimeric disintegrin Agkistrodon contortrix contortrix, inhibits angiogenesis[J].Angiogenesis, 1999;3: 259-69

[1]	CHEN Minfang, CHEN Lihua, XIE Liyun, XU Fenfen, XIA Aixiao, LIN Zhong. Preparation and the effect of antitumor of DNA plasmid lipidosome vaccine based VEGFR2 extracellular region by immunization activated in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 24-29.
[2]	YANG Guoliang, HU Dandan, XU Yikai, LOU Liming. Yiqi Huoxue decoction inhibits malignant biological behavior of human lung cancer cells via the miR-21/PTEN signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 512-518.
[3]	CAO Linzhong, WANG Xiaomin, ZHANG Hulin, GUO Chenglong, SU Lianglei, LIU Xinyu. Effects of Shenggu zaizao pills on VEGF and FLT-1 expression in steroid-induced avascular necrosis of femoral head in rabbits [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 874-880.
[4]	LI Minjiang, CHEN Dong, CHEN Wenbin. Effects of beta-adrenergic receptor blockers and COX-2 inhibitors on liver metastasis of colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 893-899.
[5]	LI Rui，KONG Yan，LIU Zenghui，LUO Shengyong. Effects of Rufuning granules on hormone levels and the expression of VEGF protein in mammary gland hyperplasia rabbits [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 138-142.
[6]	LUO Yong, LI Qi, HUA Tebo. Effects of neo-adjuvant chemotherapy combined with modified radical mastectomy on clinical effect and tumor markers in patients with breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 104-109.
[7]	YANG Hong, LIN Shan, YANG Hong, XIE Xiaowei, WANG Xin. Effect of Ira Maude on VEGF and PEDF in patients with rheumatoid arthritis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 68-71.
[8]	WAN Mei, ZHOU Zhi-ming. Research progress in effects of VEGF and MMP-9 on ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 344-348.
[9]	LUO Hui-ying, YANG Lin, WANG Xiao-peng, SU He, LIU Ying, MA Yun-tao, WU Zi-yan. Effects of siRNA silencing COX-2 gene on VEGF-C expression and cell migration in SGC-7901 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 961-966.
[10]	WU Chun-yan, WANG Wei, CHEN Xin, CHEN Dong-yun, RUI Jing. Efficacy and therapeutic mechanism of recombinant human endostatin on malignant ascites in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(5): 507-511.
[11]	CI Chao, LIU Wen-bei, CHANG Xiao-li, HE Cai-feng, QIANG Di. Expression and relationship of STAT3,VEGF and CyclinD1 in the lesions of lichen planus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(8): 874-878.
[12]	ZHANG Ye-gui, DIN Yan-xia, HOU Liang-qin. Effects of electroacupuncture combined with compound salviae miltiorrhizae on the expressions of BDNF, TrkB and VEGF in cortex of chronic cerebral ischemia rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(4): 376-381.
[13]	LV Xiao-bo, ZHOU Min, HUANG Chun-qiu, LIU Yun-mei. Experimental study of Yunnan hongyao and like product on repair-mechanism of endometrium in dysfunctional uterine bleeding rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(2): 132-136.
[14]	CHENG Yuan-guang, WU Pei. Expression of somatostatin receptor type 2 in colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(10): 1100-1104.
[15]	SONG Hai-jing, YANG Wei-zhi, ZHANG Zhuo-mei, OU Lun, Chen Fang, Wang Qing-qing, DONG Li-hou, LIU Xiu-wen. Clinical Phase I Pharmacokinetics of rhproUK [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(6): 672-676.